CVS Health Corporation

BATS-CHIXE:CVSD Stock Report

Market Cap: €54.9b

CVS Health Valuation

Is CVSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CVSD (€48.45) is trading below our estimate of fair value (€227.72)

Significantly Below Fair Value: CVSD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVSD?

Key metric: As CVSD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CVSD. This is calculated by dividing CVSD's market cap by their current earnings.
What is CVSD's PE Ratio?
PE Ratio11.4x
EarningsUS$5.02b
Market CapUS$56.98b

Price to Earnings Ratio vs Peers

How does CVSD's PE Ratio compare to its peers?

The above table shows the PE ratio for CVSD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.8x
IDHC Integrated Diagnostics Holdings
16.1x23.7%US$258.7m
CI Cigna Group
25.8x24.2%US$73.9b
SN. Smith & Nephew
35.6x22.7%UK£8.6b
MDC Mediclinic International
21.9x10.7%UK£3.7b
CVSD CVS Health
11.4x18.7%€57.0b

Price-To-Earnings vs Peers: CVSD is good value based on its Price-To-Earnings Ratio (11.4x) compared to the peer average (25.8x).

Price to Earnings Ratio vs Industry

How does CVSD's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CVSD is good value based on its Price-To-Earnings Ratio (11.4x) compared to the European Healthcare industry average (18.5x).

Price to Earnings Ratio vs Fair Ratio

What is CVSD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVSD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVSD's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVSD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€48.45
€65.09
+34.3%
14.1%€89.61€49.14n/a25
Dec ’25n/a
€65.12
0%
13.5%€88.61€54.31n/a25
Nov ’25€52.09
€64.39
+23.6%
14.4%€86.22€54.70n/a25
Oct ’25n/a
€60.07
0%
14.0%€83.22€52.79n/a25
Sep ’25n/a
€60.10
0%
13.0%€83.10€52.72n/a25
Aug ’25n/a
€62.66
0%
13.1%€86.03€53.65n/a25
Jul ’25n/a
€64.35
0%
13.4%€86.61€54.95n/a26
Jun ’25n/a
€63.62
0%
13.5%€85.73€54.39n/a26
May ’25n/a
€79.21
0%
10.8%€94.47€56.12n/a26
Apr ’25n/a
€81.91
0%
7.5%€94.31€70.50n/a26
Mar ’25n/a
€83.03
0%
7.0%€95.30€71.24n/a25
Feb ’25€68.12
€83.22
+22.2%
7.4%€95.46€73.43n/a24
Jan ’25n/a
€80.28
0%
8.6%€94.43€69.01n/a24
Dec ’24€61.24
€80.74
+31.8%
9.2%€95.52€69.81n/a23
Nov ’24n/a
€85.35
0%
10.4%€104.09€71.92€52.0923
Oct ’24n/a
€86.55
0%
10.3%€104.08€71.91n/a24
Sep ’24n/a
€85.69
0%
9.8%€102.11€70.55n/a24
Aug ’24n/a
€85.86
0%
12.2%€109.26€65.56n/a23
Jul ’24n/a
€91.39
0%
16.6%€131.57€69.93n/a24
Jun ’24€64.70
€93.41
+44.4%
16.6%€133.29€70.84n/a23
May ’24€66.41
€99.52
+49.9%
13.3%€130.34€78.39n/a22
Apr ’24€68.63
€103.83
+51.3%
10.0%€131.12€87.11n/a21
Mar ’24n/a
€107.57
0%
9.4%€134.88€89.60n/a21
Feb ’24n/a
€108.31
0%
6.5%€120.47€92.67€68.1223
Jan ’24n/a
€112.17
0%
4.9%€123.16€100.42n/a23
Dec ’23n/a
€114.03
0%
4.9%€124.98€101.91€61.2423

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:36
End of Day Share Price 2024/12/12 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CVS Health Corporation is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshit GuptaAccountability Research Corporation
Christopher GrajaArgus Research Company
Samuel HudsonAtlantic Equities LLP